150 related articles for article (PubMed ID: 35063397)
1. Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor.
Jacobi E; Solomon M; Avolio J; Shaw M; Gonska T; Ratjen F; Grasemann H
J Cyst Fibros; 2022 Mar; 21(2):e102-e105. PubMed ID: 35063397
[TBL] [Abstract][Full Text] [Related]
2. Aquagenic wrinkling of the palms in a patient with cystic fibrosis.
Grasemann H; Ratjen F; Solomon M
N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486
[No Abstract] [Full Text] [Related]
3. Aquagenic wrinkling of the palms in an adult cystic fibrosis population.
Tolland JP; Boyle J; Hall V; McKenna KE; Elborn JS
Dermatology; 2010; 221(4):326-30. PubMed ID: 20881360
[TBL] [Abstract][Full Text] [Related]
4. Aquagenic wrinkling of the palms in cystic fibrosis: comparison with controls and genotype-phenotype correlations.
Berk DR; Ciliberto HM; Sweet SC; Ferkol TW; Bayliss SJ
Arch Dermatol; 2009 Nov; 145(11):1296-9. PubMed ID: 19917960
[TBL] [Abstract][Full Text] [Related]
5. Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation.
Katz KA; Yan AC; Turner ML
Arch Dermatol; 2005 May; 141(5):621-4. PubMed ID: 15897385
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of aquagenic wrinkling of the palms in patients with cystic fibrosis and association with measurable increases in transepidermal water loss.
Arkin LM; Flory JH; Shin DB; Gelfand JM; Treat JR; Allen J; Rubenstein RC; Yan AC
Pediatr Dermatol; 2012; 29(5):560-6. PubMed ID: 22471628
[TBL] [Abstract][Full Text] [Related]
7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
8. Aquagenic wrinkling of the palms and cystic fibrosis: an Italian study with controls and genotype-phenotype correlations.
Chinazzo C; De Alessandri A; Menoni S; Romanisio G; Rebora A; Rongioletti F
Dermatology; 2014; 228(1):60-5. PubMed ID: 24434749
[TBL] [Abstract][Full Text] [Related]
9. Aquagenic Wrinkling of the Palm: A Rare Diagnostic Clue of Cystic Fibrosis and the Response to CFTR-Modulating Therapy.
Torres-Laboy PM; Melendez-Montañez JM; De Jesús-Rojas W
Cureus; 2021 Apr; 13(4):e14425. PubMed ID: 34007735
[TBL] [Abstract][Full Text] [Related]
10. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
11. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
O'Reilly R; Elphick HE
Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
[TBL] [Abstract][Full Text] [Related]
13. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
14. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
15. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
18. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
